226 related articles for article (PubMed ID: 24367169)
1. Lapatinib: new opportunities for management of breast cancer.
Liao J; Gallas M; Pegram M; Slingerland J
Breast Cancer (Dove Med Press); 2010 Nov; 2():79-91. PubMed ID: 24367169
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Tevaarwerk AJ; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
[TBL] [Abstract][Full Text] [Related]
5. [Lapatinib treatment-option in trastuzumab-resistant breast cancer].
Pikó B
Magy Onkol; 2009 Dec; 53(4):369-75. PubMed ID: 20071309
[TBL] [Abstract][Full Text] [Related]
6. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
Ma F; Ouyang Q; Li W; Jiang Z; Tong Z; Liu Y; Li H; Yu S; Feng J; Wang S; Hu X; Zou J; Zhu X; Xu B
J Clin Oncol; 2019 Oct; 37(29):2610-2619. PubMed ID: 31430226
[TBL] [Abstract][Full Text] [Related]
7. Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.
Vogel C; Chan A; Gril B; Kim SB; Kurebayashi J; Liu L; Lu YS; Moon H
Jpn J Clin Oncol; 2010 Nov; 40(11):999-1013. PubMed ID: 20542996
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib.
Nolting M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2014; 201():125-43. PubMed ID: 24756789
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer.
Paul B; Trovato JA; Thompson J
Am J Health Syst Pharm; 2008 Sep; 65(18):1703-10. PubMed ID: 18768996
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.
Frampton JE
Drugs; 2009 Oct; 69(15):2125-48. PubMed ID: 19791830
[TBL] [Abstract][Full Text] [Related]
12. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
13. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment.
Bouchalova K; Cizkova M; Cwiertka K; Trojanec R; Friedecky D; Hajduch M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2010 Dec; 154(4):281-8. PubMed ID: 21293538
[TBL] [Abstract][Full Text] [Related]
15. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer.
Kaufman B; Stein S; Casey MA; Newstat BO
Biologics; 2008 Mar; 2(1):61-5. PubMed ID: 19707428
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib.
Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2010; 184():45-59. PubMed ID: 20072830
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
Xia W; Husain I; Liu L; Bacus S; Saini S; Spohn J; Pry K; Westlund R; Stein SH; Spector NL
Cancer Res; 2007 Feb; 67(3):1170-5. PubMed ID: 17283152
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
Storniolo AM; Pegram MD; Overmoyer B; Silverman P; Peacock NW; Jones SF; Loftiss J; Arya N; Koch KM; Paul E; Pandite L; Fleming RA; Lebowitz PF; Ho PT; Burris HA
J Clin Oncol; 2008 Jul; 26(20):3317-23. PubMed ID: 18490651
[TBL] [Abstract][Full Text] [Related]
20. Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer.
Abramovitz M; Williams C; Loibl S; Leyland-Jones B
Clin Breast Cancer; 2016 Dec; 16(6):444-455. PubMed ID: 27435628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
